Diaceutics’ (DXRX) Buy Rating Reiterated at Canaccord Genuity Group

Canaccord Genuity Group reissued their buy rating on shares of Diaceutics (LON:DXRX) in a research note released on Tuesday morning,Digital Look reports. The brokerage currently has a GBX 215 price objective on the stock.

Diaceutics Stock Up 0.8%

Shares of Diaceutics stock opened at GBX 193 on Tuesday. Diaceutics has a twelve month low of GBX 125 and a twelve month high of GBX 197. The company has a current ratio of 2.55, a quick ratio of 9.92 and a debt-to-equity ratio of 5.40. The business’s 50 day simple moving average is GBX 148.17 and its 200-day simple moving average is GBX 151.55. The stock has a market capitalization of £163.78 million, a price-to-earnings ratio of 1,754.55 and a beta of 0.88.

Diaceutics (LON:DXRX) last released its quarterly earnings data on Tuesday, September 22nd. The company reported GBX (3.27) earnings per share for the quarter. Diaceutics had a negative return on equity of 0.68% and a negative net margin of 0.66%. Equities research analysts forecast that Diaceutics will post 1.0107919 earnings per share for the current year.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.